Companies GALECTIN THERAPEUTICS INC
GALECTIN THERAPEUTICS (GALT): executive pay, fiscal 2025
Free brief. Every figure links to the company’s own filing.
Email me GALECTIN THERAPEUTICS INC’s executive pay brief as a PDF
It arrives in about 2 minutes, with every figure cited to its filing.
After the PDF, up to three short notes on the deeper reports for this company. Reply “unsubscribe” to any of them, any time.
CEO pay, last three years
- $963,647FY2023
- $1,189,674FY2024
- $1,174,782FY2025
CEO total pay was $1,174,782 in fiscal 2025, down from $1,189,674 in fiscal 2024.
FY2025: salary $624,000 · bonus $312,000 · stock awards $182,763
Order GALT
Add the email the receipt and the PDF go to, then press the report you want. Each button opens its own card payment on Stripe.
Executives and directors
Full detail
Every table from the filing. Open any section.
Summary compensation table
| Named executive officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension / NQDC | All other | Total |
|---|---|---|---|---|---|---|---|---|
| Joel Lewis | $624,000 | $312,000 | $182,763 | — | — | — | $56,019 | $1,174,782 |
| Chief Executive Officer & President | ||||||||
| Jack Callicutt | 400,000 | 220,000 | 130,545 | — | — | — | 56,019 | 806,564 |
| Chief Financial Officer | ||||||||
A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed in the filing, without adjustment.
Three-year trend — total compensation per named executive
| Named executive officer | FY2025 total | FY2024 total | FY2023 total | Δ FY2024→2025 |
|---|---|---|---|---|
| Joel Lewis | $1,174,782 | $1,189,674 | $963,647 | ↓ −14,892 |
| Jack Callicutt | 806,564 | 716,945 | 561,419 | ↑ +89,619 |
Prior-year totals as disclosed in the corresponding proxy; deltas are computed values with the derivation shown in the register.
Incentive-plan design — the Compensation Discussion & Analysis
The Company provides a competitive total compensation package through a combination of base salary, annual performance bonuses, and long-term equity awards to attract, retain, and reward qualified executives. The program is designed to align executive interests with corporate success and stockholder interests by making a portion of compensation dependent upon performance and including long-term equity incentives.
| CEO STI target (% of salary) | 50% |
|---|---|
| CEO LTI target (% of salary) | — |
| Independent consultant | Barney & Barney LLC |
| Clawback policy | True |
| Anti-hedging | False |
| Anti-pledging | false |
Equity grants and outstanding awards
No plan-based awards are on file for this fiscal year.
Outstanding equity awards at fiscal year-end 2025
| Executive | Award | Shares unvested | Exercise price | Market value unvested |
|---|---|---|---|---|
| Jack Callicutt | Option | 32,500 | 1.23 | — |
| Joel Lewis | Option | 45,500 | 1.23 | — |
Director compensation
| Director | Cash fees | Stock awards | Option awards | Non-equity incentive | All other | Total |
|---|---|---|---|---|---|---|
| Kevin D. FreemanIndependent · Compensation · Audit · Nominating and Corporate Governance | $56,000 | $0 | $52,260 | $0 | $0 | $108,260 |
| Gilbert F. Amelio, Ph.DIndependent · Compensation · Nominating and Corporate Governance (Chair) | 55,500 | 0 | 52,260 | 0 | 0 | 107,760 |
| Richard A. ZordaniIndependent · Audit (Chair) | 55,000 | 0 | 52,260 | 0 | 0 | 107,260 |
| Gilbert S. Omenn, M.D., Ph.DIndependent · Compensation (Chair) | 50,000 | 0 | 52,260 | 0 | 0 | 102,260 |
| Kary EldredIndependent · Audit | 47,500 | 0 | 52,260 | 0 | 0 | 99,760 |
| Marc Rubin, M.DIndependent · Departed during FY | 43,500 | 0 | 52,260 | 0 | 0 | 95,760 |
| Elissa J. Schwartz, Ph.DIndependent · Nominating and Corporate Governance | 43,500 | 0 | 52,260 | 0 | 0 | 95,760 |
| Benjamin S. Carson Sr., M.DIndependent · Nominating and Corporate Governance | 40,000 | 0 | 52,260 | 0 | 0 | 92,260 |
| Richard E. UihleinIndependent · Board Chair | 0 | 40,000 | 52,260 | 0 | 0 | 92,260 |
| Harold H. ShlevinIndependent | 40,000 | 0 | 52,260 | 0 | 0 | 92,260 |
| Joel LewisEmployee director | — | — | — | — | — | 0 |
| Henry Brem, M.DNewly elected | — | — | — | — | — | — |
Board fee structure and ownership guideline
| Annual cash retainer | $35,000 |
|---|---|
| Annual equity retainer | — |
| Per board meeting fee | — |
| Committee chair fees (audit / comp / nom-gov) | 7,500 / 5,000 / 3,500 |
| Stock ownership guideline | — |
Total cost of the board
| Component | FY2025 |
|---|---|
| Cash retainers and fees | $431,000 |
| Equity awards (grant-date value) | $40,000 |
| All other compensation | $0 |
| Total cost of the board | $471,000 |
Computed as the sum of the director compensation table rows above; inputs and formula shown in the register.
Peer group, and who names GALECTIN THERAPEUTICS as a peer
Companies that benchmark against GALT
1 company names GALT as a compensation peer
- DiaMedica Therapeutics Inc.DMACFY2025
Each company listed discloses GALT in its own benchmarking peer group, as disclosed in each company's most recent proxy statement within the last two proxy seasons. Two companies are therefore absent by design: one that named GALT in an earlier year and no longer does, and one whose own most recent disclosure is older than the last two seasons.
Chief executive pay against the peer group
Most recent fiscal-year chief executive compensation at each disclosed peer, taken from that company’s own proxy statement.
| Rank | Company | FY | Chief executive | Salary | Stock awards | Option awards | Non-equity incentive | Total |
|---|---|---|---|---|---|---|---|---|
| 1 | GALECTIN THERAPEUTICS INC | 2025 | Joel Lewis | $624,000 | $182,763 | — | — | $1,174,782 |
Each peer’s compensation is from its most recently filed proxy; fiscal years differ by company. Each peer’s figures come from its own filings; the subject company is highlighted. Peers whose chief executive compensation is outside our coverage universe are stated as such, never left blank.
Say-on-pay history and pay ratio
| Meeting year | Meeting date | For | Against | Abstain | Support | Outcome |
|---|---|---|---|---|---|---|
| 2025 | 2025-12-03 | 25,260,489 | 639,415 | 310,420 | 97.53% | Passed |
| 2022 | 2022-12-01 | 16,271,959 | 1,450,200 | 428,140 | 91.82% | Passed |
| 2019 | 2019-12-04 | 20,584,969 | 2,767,101 | 557,416 | 88.15% | Passed |
| 2016 | 2016-12-15 | 10,263,034 | 844,997 | 142,823 | 92.39% | Passed |
Rows are labeled by annual-meeting year, with the meeting date beside each; the vote held in a given year acts on the prior fiscal year’s compensation.
Say-on-pay — history, company’s computation
| Meeting year | Meeting date | Approval — company’s computation |
|---|---|---|
| 2025 | 2025-12-03 | 97.53%a |
| 2022 | 2022-12-01 | 91.82%b |
| 2019 | 2019-12-04 | 88.15%c |
a. Voting standard not stated in the filing.
b. Voting standard not stated in the filing.
c. Voting standard not stated in the filing.
Approval percentages are the company’s own reported computations under its own stated standard, not recomputed by Velarion. Where a company does not state a standard, none is assumed.
Insider trades since the proxy
No insider equity transactions reported since the proxy statement.
Sources (20 citations)
Each figure is listed with the filing it comes from, where it appears in that filing, and the value as printed. Any figure can be independently confirmed against the source.
- Section 01, Joel Lewis. DEF 14A, filed 2026-10-13. Section “SUMMARY COMPENSATION TABLE” · page 29. As printed: 1,174,782. View filing ↗
- Section 01, Jack Callicutt. DEF 14A, filed 2026-10-13. Section “SUMMARY COMPENSATION TABLE” · page 29. As printed: 806,564. View filing ↗
- Section 08, Kevin D. Freeman. DEF 14A, filed 2026-10-13. Section “Director Compensation”. As printed: 108,260. View filing ↗
- Section 08, Gilbert F. Amelio, Ph.D. DEF 14A, filed 2026-10-13. Section “Director Compensation”. As printed: 107,760. View filing ↗
- Section 08, Richard A. Zordani. DEF 14A, filed 2026-10-13. Section “Director Compensation”. As printed: 107,260. View filing ↗
- Section 08, Gilbert S. Omenn, M.D., Ph.D. DEF 14A, filed 2026-10-13. Section “Director Compensation”. As printed: 102,260. View filing ↗
- Section 08, Kary Eldred. DEF 14A, filed 2026-10-13. Section “Director Compensation”. As printed: 99,760. View filing ↗
- Section 08, Marc Rubin, M.D. DEF 14A, filed 2026-10-13. Section “Director Compensation”. As printed: 95,760. View filing ↗
- Section 08, Elissa J. Schwartz, Ph.D. DEF 14A, filed 2026-10-13. Section “Director Compensation”. As printed: 95,760. View filing ↗
- Section 08, Benjamin S. Carson Sr., M.D. DEF 14A, filed 2026-10-13. Section “Director Compensation”. As printed: 92,260. View filing ↗
- Section 08, Richard E. Uihlein. DEF 14A, filed 2026-10-13. Section “Director Compensation”. As printed: 92,260. View filing ↗
- Section 08, Harold H. Shlevin. DEF 14A, filed 2026-10-13. Section “Director Compensation”. As printed: 92,260. View filing ↗
- Section 08, Joel Lewis. DEF 14A, filed 2026-10-13. Section “Director Compensation”. As printed: 0. View filing ↗
- Section 08, Henry Brem, M.D. DEF 14A, filed 2026-10-13. Section “Director Compensation”. As printed: —. View filing ↗
- Section 06, 2025 vote. Form 8-K, filed 2025-12-08. Item 5.07 · say-on-pay result. As reported: 97.53% (votes for as printed: 25,260,489). View filing ↗
- Section 06, 2022 vote. Form 8-K, filed 2022-12-06. Item 5.07 · say-on-pay result. As reported: 91.82% (votes for as printed: 16,271,959). View filing ↗
- Section 06, 2019 vote. Form 8-K, filed 2019-12-06. Item 5.07 · say-on-pay result. As reported: 88.15% (votes for as printed: 20,584,969). View filing ↗
- Section 01 trend, Δ column (computed). Computed. Δ = current-FY total − prior-FY total per named officer.
- Section 09b board cost (computed). Computed. Cash 431,000 + equity 40,000 + all other 0 = 471,000, summed across the director compensation table rows.
- GALECTIN THERAPEUTICS INC (subject), Section 10b CEO total. DEF 14A, filed 2026-10-13. CEO total compensation as printed in GALECTIN THERAPEUTICS INC's own proxy. As printed: 1,174,782. View filing ↗